Featured Press Releases

AI Utilized by TNF Pharmaceuticals and Renova Health to Accelerate Drug Development

AI Utilized by TNF Pharmaceuticals and Renova Health to Accelerate Drug Development

Kiromic BioPharma reports positive results from third patient in Deltacel-01 trial

Kiromic BioPharma reports positive results from third patient in Deltacel-01 trial

  • 02 Apr 2024

Kiromic BioPharma, Inc. reports early efficacy results showing tumor stabilization in the third...

Genprex collaborators to present positive preclinical data on Reqorsa® gene therapy

Genprex collaborators to present positive preclinical data on Reqorsa® gene therapy

Fresenius Kabi’s biosimilars Conexxence® and Bomyntra® (denosumab-bnht) receive interchangeable designation from the FDA

Fresenius Kabi’s biosimilars Conexxence® and Bomyntra® (denosumab-bnht) receive interchangeable designation from the FDA

Epia Neuro Launches Intent-Driven Neural Technology to Restore Function After Stroke and Address Cognitive Decline

Epia Neuro Launches Intent-Driven Neural Technology to Restore Function After Stroke and Address Cognitive Decline

IMAAVY® (nipocalimab-aahu) demonstrated rapid onset and durable hemoglobin response in a pivotal Phase 2/3 study of warm autoimmune hemolytic anemia (wAIHA), a disease with no FDA-approved therapies

IMAAVY® (nipocalimab-aahu) demonstrated rapid onset and durable hemoglobin response in a pivotal Phase 2/3 study of warm autoimmune hemolytic anemia (wAIHA), a disease with no FDA-approved therapies

SEREMI de Salud Grants Registration to Chile

SEREMI de Salud Grants Registration to Chile's First Finished Product Featuring Setria® Glutathione

  • Kyowa Hakko U.S.A
  • 11 Jun 2026
Roquette Highlights Scalable Innovations in Drug Delivery

Roquette Highlights Scalable Innovations in Drug Delivery

  • Roquette
  • 11 Jun 2026
X-Therma Launched XT-NoVo® and TimeSeal® Platform to Advance On-Demand Regenerative Medicine Beyond Cold Chain Constraints

X-Therma Launched XT-NoVo® and TimeSeal® Platform to Advance On-Demand Regenerative Medicine Beyond Cold Chain Constraints

  • X-Therma Inc.
  • 11 Jun 2026
IMAAVY® (nipocalimab-aahu) demonstrated rapid onset and durable hemoglobin response in a pivotal Phase 2/3 study of warm autoimmune hemolytic anemia (wAIHA), a disease with no FDA-approved therapies

IMAAVY® (nipocalimab-aahu) demonstrated rapid onset and durable hemoglobin response in a pivotal Phase 2/3 study of warm autoimmune hemolytic anemia (wAIHA), a disease with no FDA-approved therapies

  • Johnson & Johnson
  • 10 Jun 2026
Exilby®, a First-in-Class Non-Opioid Treatment for Chronic Low Back Pain, Receives Its First European Marketing Authorization from VERTANICAL; Pivotal U.S. Phase 3 Trial Underway

Exilby®, a First-in-Class Non-Opioid Treatment for Chronic Low Back Pain, Receives Its First European Marketing Authorization from VERTANICAL; Pivotal U.S. Phase 3 Trial Underway

  • Vertanical
  • 09 Jun 2026
BEACON Real-World Study Shows Positive Top-Line Results for ZUNVEYL® in Alzheimer’s Disease, Reports Alpha Cognition

BEACON Real-World Study Shows Positive Top-Line Results for ZUNVEYL® in Alzheimer’s Disease, Reports Alpha Cognition

  • Alpha Cognition Inc.
  • 09 Jun 2026
The Digital Pharma Advances Conference 2026

Most Popular
June   2026
M T W T F S S
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.